Filing identity and period
The supplied filing is Signal Genetics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015—not a filing for Viridian Therapeutics, Inc. The summary below reflects the filing text provided; confirm the issuer before relying on it.
Business context
Signal Genetics was a commercial-stage molecular diagnostics company whose revenue primarily came from its MyPRS multiple myeloma test. It operated in one segment in the United States. UAMS was its largest customer and research-program partner.
Financial results and liquidity
Amounts are in thousands of dollars except per-share data and test counts.
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Net revenue | $645 | $1,091 |
| Cost of revenue | $760 | $731 |
| Gross profit (loss) | $(115) | $360 |
| Operating expenses | $3,257 | $1,258 |
| Operating loss | $(2,612) | $(167) |
| Interest expense | $22 | $539 |
| Net loss | $(2,634) | $(706) |
| Net loss per share | $(0.45) | $(3.53) |
| Cash used in operating activities | $(1,109) | Cash provided: $85 |
Gross margin was approximately negative 18% versus positive 33% a year earlier. Cash was $13.268 million at March 31, 2015, compared with $5.119 million at year-end 2014. Current assets were $14.491 million and current liabilities $2.495 million, yielding working capital of approximately $12.0 million. Total assets were $15.747 million; stockholders’ equity was $13.149 million. The balance sheet included a $1.058 million related-party note payable and $148,000 in capital-lease obligations.
Cash increased by $8.149 million during the quarter, primarily from $9.302 million of net financing cash flow, including proceeds from a February stock offering. Investing cash use was $44,000. The company reported no material capital expenditure commitments.
Changes versus prior period
- Revenue fell 41% to $645,000; tests billed declined 10% to 777. UAMS research-program revenue decreased 37%, which management attributed principally to reduced funding available at UAMS.
- Contractual allowances rose to 51% of gross revenue from 26%. Management cited estimates for non-contracted payors and recorded $30,000 of unfavorable prior-year revenue adjustments.
- Operating expenses increased to $3.257 million from $1.258 million, reflecting higher staffing and public-company costs, sales and marketing expansion, and $708,000 of stock-based compensation.
- Interest expense declined substantially from $539,000, mainly because related-party debt had been converted to equity in June 2014.
- In February 2015, the company raised net cash proceeds of approximately $9.2 million from a public offering and overallotment. Shares outstanding were 7,504,990 at quarter-end.
Outlook, risks, and unusual items
- Management expected continued losses and negative operating cash flows while expanding sales, marketing, and research and development, but believed cash on hand would support operations for at least one year after the report date. It cautioned that further financing might be needed and was not assured.
- Management expected continued downward pressure on UAMS research-program revenue for the rest of 2015 and planned further sales-force and marketing expansion. No quantitative revenue or earnings guidance was provided.
- Key business risks include dependence on UAMS, uncertain reimbursement and collections from non-contracted payors, possible reductions in payor reimbursement, and reliance on a single supplier for testing inventory. UAMS-sourced revenue represented 77% of Q1 2015 net revenue.
- Net accounts receivable were $598,000; gross receivables were $1.904 million and included $1.101 million over 90 days, offset by $1.306 million in contractual and doubtful-account allowances. Days sales outstanding was 83.
- The company reported no current legal proceedings and no material changes to the risk factors in its 2014 annual report. Management said disclosure controls were effective; it had not yet assessed internal control over financial reporting under Section 404.
Important facts to verify
- Confirm the issuer: the provided filing identifies Signal Genetics, Inc., whereas the request names Viridian Therapeutics, Inc.
- Review the offering proceeds, share-count changes, and related-party note terms, including the 8% interest rate and demand feature.
- Assess the collectability and estimate sensitivity of non-contracted-payor receivables and the resulting contractual allowances.
- Evaluate the company’s cash runway against its losses, planned spending, and stated possibility of needing additional financing.
- Check the source filing for any omitted details; this summary is based only on the supplied text.